• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
ConclusionRIV  + ASA was a cost-effective treatment alternative compared with ASA in patients with CCS or symptomatic PAD in Finland.
Source: Advances in Therapy - June 8, 2020 Category: Drugs & Pharmacology Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

How fast can acute stroke treatment become to still be reliable?
(University of Helsinki) Neurologists around the world are aware that the delivery of thrombolytic treatment for stroke in Helsinki University Hospital, Finland, is freaking fast -- but is it too fast? A new study published on July 11 in the journal Neurology clarified whether the team of neurologists in Helsinki actually have enough time to diagnose stroke correctly before it is treated.
Source: EurekAlert! - Medicine and Health - July 13, 2018 Category: International Medicine & Public Health Source Type: news

Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation, p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.
Source: Journal of Thrombosis and Haemostasis - October 10, 2013 Category: Hematology Authors: M. Puurunen, P. Salo, S. Engelbarth, K. Javela, M. Perola Tags: Original Article Source Type: research